Evidence map›Paper›PMID 42292532›Full record

SynthesisInternational journal of chronic obstructive pulmonary disease2026

Global Economic and Social Burden of Chronic Obstructive Pulmonary Disease: A Systematic Review (2020-2024).

Celia Gutiérrez-Villegas, Manuel Herrero-Montes, Luis Manuel Fernández Cacho, Carlos Antonio Amado-Diago, Valentín Perales-García, Andrea Marcela Aceros Lora, María Paz-Zulueta

Abstract readSystematic Review
In one paragraph

Synthesis in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Celia Gutiérrez-VillegasNursing Research Group, Marqués de Valdecilla Health Research Institute (IDIVAL), Santander, Cantabria, Spain.ORCID 0009-0005-1189-1210
Manuel Herrero-MontesNursing Research Group, Marqués de Valdecilla Health Research Institute (IDIVAL), Santander, Cantabria, Spain.ORCID 0000-0002-5732-8344
Luis Manuel Fernández CachoUniversidad de Cantabria (UC), Santander, Cantabria, Spain.
Carlos Antonio Amado-DiagoUniversidad de Cantabria (UC), Santander, Cantabria, Spain.
Valentín Perales-GarcíaCantabrian Healthcare Service, Santander, Cantabria, Spain.ORCID 0009-0000-8596-1051
Andrea Marcela Aceros LoraUniversity Hospital of Santander, Bucaramanga, Santander, Colombia.
María Paz-ZuluetaUniversidad de Cantabria (UC), Santander, Cantabria, Spain.ORCID 0000-0003-3025-9892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a leading cause of morbidity and mortality worldwide and imposes a substantial economic and social burden on healthcare systems and society. Objective: To analyse recent evidence (2020-2024) on the economic and social burden of COPD, including direct, indirect, and intangible costs. Methods: A systematic review was conducted to synthesise recent evidence on the economic and social burden of COPD published between January 2020 and December 2024. Searches were performed in PubMed/MEDLINE, Scopus, and Web of Science. Original studies reporting direct healthcare costs, direct non-healthcare costs, indirect costs or intangible costs related to health-related quality of life (HRQoL) were included. Results: Thirty studies from 15 countries were included. Direct healthcare costs represent the main component of expenditure, largely driven by hospitalisations and exacerbations. Annual costs ranged from €3500 to €10,000 per patient in Europe and from US$10,000 to US$17,000 in the United States. Although absolute costs were lower in Asia, the relative financial burden on patients was considerable. Direct non-healthcare costs, including out-of-pocket expenses and long-term care, were particularly relevant in severe disease. Indirect costs related to productivity losses and unemployment were substantial and, in some middle-income countries, exceeded healthcare costs. Intangible costs included anxiety, depression, caregiver distress, impaired quality of life, and perceived financial toxicity, with high overall prevalence. Conclusion: COPD creates a considerable economic and social burden. Although direct costs are predominant, indirect, and intangible costs are decisive, particularly in contexts with lower healthcare coverage. Clinical factors (severity, exacerbations, and comorbidities) and socio-economic factors (educational level, income, and employment) explain much of the variability. A holistic approach that addresses health, social, and emotional dimensions is required for a more equitable and sustainable management.

Indexed as

Cost of IllnessGlobal HealthHealth Care CostsPulmonary Disease, Chronic ObstructiveHealth ExpendituresHumansQuality of Lifechronic obstructive pulmonary diseaseCOPDdirect healthcare costhealth-related quality of lifeHRQoLindirect costintangible costsocioeconomic impact

Identifiers

PMID42292532
PMCPMC13254701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.